SEC Form D raise Raised $2M (Form D filed Nov 3, 2025); 5 roles open. SEC Form D 0001493152-25-020624 (Nov 3, 2025)Evidence (1 event)
Nov 3, 2025 · SEC Form D 0001493152-25-020624 Name of Issuer: Celularity Inc; CIK: 1752828; Address: Florham Park, NJ; Submission type: D; Filing date: 2025-11-03; Industry Group: Biotechnology; Date of First Sale: 2025-10-24; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6666667; Total Amount Sold: 2000000; Federal exemptions: 06c
Raise Private placement: $10M (total, as published), announced Sep 24, 2026. Source: company release on GlobeNewswire. source ↗
Raise Private placement: $35M (total, as published), announced Mar 10, 2026. Source: SEC filing. source ↗
Raise Private placement: $7M (total, as published), announced Dec 22, 2025. Source: SEC filing. source ↗
Partnership Partnership / licensing announced Feb 24, 2025. Source: SEC filing. source ↗
Trial start Phase 1/Phase 2: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aden source ↗
Trial start Phase 1/Phase 2: CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type source ↗
Trial start Phase 1: Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM source ↗
Trial start Phase 1/Phase 2: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 source ↗
Trial start Phase 1: Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma source ↗
Trial start Phase 1: Natural Killer Cell (CYNK-001) Infusions in Adults with AML source ↗
Trial start Phase 1: A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous source ↗
Trial start Phase 1: A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory source ↗
Trial start Phase 2: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy source ↗
Trial start Phase 2: Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease source ↗
Trial start Phase 2: Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD. source ↗
Trial start Phase 1: Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers source ↗
Trial start Phase 1: A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of source ↗
Trial start Phase 1: Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis source ↗
Trial start Phase 2: Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke source ↗
Trial start Phase 2: Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis source ↗
Trial start Phase 2: PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease source ↗
Funding
Raised: $52.0M. Last 2 years.
Private placement: $10M (total, as published), announced Sep 24, 2026. Source: company release on GlobeNewswire. source ↗
Private placement: $35M (total, as published), announced Mar 10, 2026. Source: SEC filing. source ↗
Private placement: $7M (total, as published), announced Dec 22, 2025. Source: SEC filing. source ↗
Partnership / licensing announced Feb 24, 2025. Source: SEC filing. source ↗
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
